Place · Level 3 · Condition
Hyperuricemia
中国成人 ~ 13% · 男 > 7 / 女 > 6 mg/dL · 90% 是排泄差不是合成多 · 多数无症状不必用药 · 与痛风、尿酸结石 / CKD / 代谢综合征同源
Story path
Chapter 1
Threshold · epi · vs gout
Threshold · epi · vs gout
Hyperuricemia is a lab finding, not a disease. The clinical definition is straightforward: serum urate (SUA) > 7 mg/dL (420 µmol/L) in men, > 6 mg/dL (360 µmol/L) in women. This threshold isn't a 'lower is better' health target — it's the level at which SUA in plasma approaches its physical saturation point (~ 6.8 mg/dL). Above that, crystals can form.
SUA ≠ gout — the first thing this atlas wants to be clear about:
People with high SUA outnumber people with gout by far: in Chinese adults, hyperuricemia prevalence is about 13.3% (men 19.4% / women 7.9%), while true gout prevalence is only 1.1% (Liu 2015 meta-analysis)Roughly only one in ten people with hyperuricemia will actually experience a gout flare in their lifetime — most simply carry an elevated SUA on lab reports forever, with no crystal depositionThat's why this island gives hyperuricemia its own scene: panicking at a red lab value (→ strict diet → repeated clinic visits) is a common overreaction
Global trend + younger ages:
Chinese hyperuricemia prevalence has nearly doubled in 30 years, tracking the sugary-drink curve + urbanisation + obesity (see the atlas gout scene)In the 1980s it was largely a 50+ male diagnosis; in 2020s China, men 18-35 are the fastest-growing demographicUS NHANES shows ~ 20% adult prevalence, rising alongside metabolic syndromePremenopausal women have markedly lower SUA than men (estrogen promotes renal excretion); the gap narrows quickly after menopause — see the atlas perimenopause island
Why most people are surprised by the result:
Hyperuricemia is almost entirely asymptomatic — unlike high glucose (thirst, fatigue) or high blood pressure (occasional headache)It is usually 'incidentally discovered' at routine check-ups, at the first gout flare, or at the first kidney-stone presentationIn China, SUA is part of standard adult check-ups; in the US it is not, and patients need to request it
Common misreadings of a high SUA report:
'Mildly elevated (7.5 mg/dL) = must start medication now': no — see the ULT decision scene below'I have a family history, my SUA is high, so I'll get gout': increased risk, not inevitability — long-term management starts at family history + high SUA + ≥ 1 confirmed flare'I've never had a flare, so I can ignore this': hyperuricemia has consequences beyond gout — see the multi-organ scene'Lower is always better': not really — very low SUA (< 2 mg/dL) has been linked to neurodegenerative risk; the clinical target is 'below saturation + no flares', not 'as low as possible'
SUA ≠ gout — the first thing this atlas wants to be clear about:
People with high SUA outnumber people with gout by far: in Chinese adults, hyperuricemia prevalence is about 13.3% (men 19.4% / women 7.9%), while true gout prevalence is only 1.1% (Liu 2015 meta-analysis)Roughly only one in ten people with hyperuricemia will actually experience a gout flare in their lifetime — most simply carry an elevated SUA on lab reports forever, with no crystal depositionThat's why this island gives hyperuricemia its own scene: panicking at a red lab value (→ strict diet → repeated clinic visits) is a common overreaction
Global trend + younger ages:
Chinese hyperuricemia prevalence has nearly doubled in 30 years, tracking the sugary-drink curve + urbanisation + obesity (see the atlas gout scene)In the 1980s it was largely a 50+ male diagnosis; in 2020s China, men 18-35 are the fastest-growing demographicUS NHANES shows ~ 20% adult prevalence, rising alongside metabolic syndromePremenopausal women have markedly lower SUA than men (estrogen promotes renal excretion); the gap narrows quickly after menopause — see the atlas perimenopause island
Why most people are surprised by the result:
Hyperuricemia is almost entirely asymptomatic — unlike high glucose (thirst, fatigue) or high blood pressure (occasional headache)It is usually 'incidentally discovered' at routine check-ups, at the first gout flare, or at the first kidney-stone presentationIn China, SUA is part of standard adult check-ups; in the US it is not, and patients need to request it
Common misreadings of a high SUA report:
'Mildly elevated (7.5 mg/dL) = must start medication now': no — see the ULT decision scene below'I have a family history, my SUA is high, so I'll get gout': increased risk, not inevitability — long-term management starts at family history + high SUA + ≥ 1 confirmed flare'I've never had a flare, so I can ignore this': hyperuricemia has consequences beyond gout — see the multi-organ scene'Lower is always better': not really — very low SUA (< 2 mg/dL) has been linked to neurodegenerative risk; the clinical target is 'below saturation + no flares', not 'as low as possible'
Chapter 2
Mechanism · XO + excretion
Mechanism · XO + excretion
Understanding why SUA is high means looking at production and excretion as two legs. Most people assume 'high SUA = I eat too much purine,' but clinically about 90% of hyperuricemia is under-excretion, not over-production.
Production side · purine → xanthine → urate:
About 70% of body urate is endogenous (apoptosis + DNA turnover + energy metabolism); 30% is dietaryThe last two steps (hypoxanthine → xanthine → urate) are both catalysed by xanthine oxidase (XO) — this is why allopurinol and febuxostat both work by inhibiting XO (see the ULT scene)A key human-vs-other-mammal difference: uricase became a pseudogene ~ 15 million years ago in our lineage — we cannot, like dogs, further degrade urate into more soluble allantoin. So urate accumulates in blood and waits for excretion
Excretion side · kidney + gut:
~ 2/3 renal (urine)~ 1/3 enteric (gut microbial metabolism + stool)The renal route is the dominant lever. In the tubule, three transporters decide whether urate is reclaimed or excreted
Three transporters · the source of individual variation:
URAT1 (SLC22A12): distal-tubule urate reabsorption channel. For most people, the SUA set-point is essentially set hereGLUT9 (SLC2A9): bidirectional transporter, mainly affects tubular reabsorptionABCG2: gut + renal efflux of urate. Loss-of-function variants are common in East Asian populations and are a major genetic basis for early-onset hyperuricemia in China / Japan / KoreaCombined, variation in these three genes explains most of the 'same diet / same BMI, why is my urate high and his isn't?' puzzles
Production side · purine → xanthine → urate:
About 70% of body urate is endogenous (apoptosis + DNA turnover + energy metabolism); 30% is dietaryThe last two steps (hypoxanthine → xanthine → urate) are both catalysed by xanthine oxidase (XO) — this is why allopurinol and febuxostat both work by inhibiting XO (see the ULT scene)A key human-vs-other-mammal difference: uricase became a pseudogene ~ 15 million years ago in our lineage — we cannot, like dogs, further degrade urate into more soluble allantoin. So urate accumulates in blood and waits for excretion
Excretion side · kidney + gut:
~ 2/3 renal (urine)~ 1/3 enteric (gut microbial metabolism + stool)The renal route is the dominant lever. In the tubule, three transporters decide whether urate is reclaimed or excreted
Three transporters · the source of individual variation:
URAT1 (SLC22A12): distal-tubule urate reabsorption channel. For most people, the SUA set-point is essentially set hereGLUT9 (SLC2A9): bidirectional transporter, mainly affects tubular reabsorptionABCG2: gut + renal efflux of urate. Loss-of-function variants are common in East Asian populations and are a major genetic basis for early-onset hyperuricemia in China / Japan / KoreaCombined, variation in these three genes explains most of the 'same diet / same BMI, why is my urate high and his isn't?' puzzles
Phenotyping + diet limits + drug effects
'Over-production vs under-excretion' clinical phenotyping (24-h urine urate):Under-excretion ~ 90%: 24-h urine urate < 800 mg / < 600 mg on a purine-restricted dietOver-production ~ 10%: high 24-h urine urate + high SUA. Seen in lymphoma / leukaemia chemotherapy (tumour lysis syndrome — emergency) / rare enzyme defects (Lesch-Nyhan) / severe obesity / heavy alcohol useThis phenotyping is not routine — useful only for refractory gout, recurrent stones, or drug selection
Why 'just diet' has limited impact:
Of the dietary 30%, much comes from plant purines, which do not significantly raise gout risk (Choi 2004 NEJM)The 70% endogenous urate doesn't go away when you go vegetarianThe real lever for most readers is reducing insulin resistance + waist circumference + cutting sugary drinks (all improve excretion) — not the 1980s textbook 'no seafood, no organs, no tofu, no spinach' list
Drugs / states with hidden effects on excretion:
Thiazide + loop diuretics: directly ↓ excretion → the most common 'pressed BP, raised SUA' source in clinicLow-dose aspirin (< 1 g/day): ↓ excretion; paradoxically high-dose aspirin promotes excretion, but high-dose isn't used clinicallyCiclosporin + tacrolimus: post-transplant hyperuricemia is very commonChronic lead exposure: historical 'saturnine gout' from lead (rare now, but old pipes / industrial exposure still exist)Dehydration + post-exercise lactate ↑: competes with urate for tubular excretion → transient SUA riseStarvation / very-low-calorie / keto induction: ketones compete for tubular excretion → SUA spikes → can trigger a gout flare. This is the classic 'lost weight too fast and had my first flare' story
Atlas linkbacks: `fructose-metabolism/khk` L4 (fructose → AMP → urate generation) · `gout` (same island) · `kidney-stones` (uric-acid stones = 10-15% of all stones) · `endocrine/metabolic-syndrome` (insulin suppresses URAT1 excretion → high insulin = high urate).
Chapter 3
Beyond gout · multi-organ
Beyond gout · multi-organ
The clinical concern with hyperuricemia isn't only 'will I get gout?'. There are three under-recognised long-term chains — particularly poorly recognised in young Chinese men.
Chain 1 · Kidney:
Uric-acid stones: 10-15% of all kidney stones; unlike typical calcium-oxalate stones, they crystallise easily at urine pH < 5.5, appear low-density but visible on CT, and are nearly radiolucent on plain X-ray — which is why some patients with 'flank pain + haematuria but negative X-ray' are misdiagnosed for years. See the atlas `kidney-stones` sceneChronic urate nephropathy: long-term high SUA → urate crystal deposition in renal interstitium → chronic inflammation → tubulo-interstitial damage → gradual eGFR decline. Not inevitable, but patients with SUA > 10 mg/dL long-term show clearly accelerated CKD progressionAcute urate nephropathy (emergency): chemotherapy-induced tumour lysis syndrome (TLS) / severe dehydration + heavy alcohol / rare enzyme defects → SUA spikes → crystals block tubules → acute kidney injury. Emergency — see the red-flag sceneThe causality is partial: acute is clearly causal; chronic is partly causal in observational studies but Mendelian randomisation suggests SUA's causal effect on CKD is weaker than the observed association — meaning a large portion of 'high SUA + CKD' reflects shared metabolic background (hypertension + IR + MetSyn) acting on both organs
Chain 2 · Cardiovascular:
Observational links to hypertension, heart failure, CHD, and stroke — overall 'association + plausible mechanism + causality not fully established'Mechanism candidates: high SUA → endothelial dysfunction + oxidative stress + renin-angiotensin activation + microvascular inflammationKey clinical data: the CARES 2018 trial showed febuxostat had higher cardiovascular mortality vs allopurinol (not a test of treating hyperuricemia per se, but a reminder that 'urate-lowering drug effects on cardiovascular outcomes' are not neutral)Clinical implication: treating elevated SUA purely to reduce cardiovascular events is not recommended by any major guideline (ACR 2020 / EULAR 2016 / CSR 2024). In cardiovascular risk assessment, SUA is a 'warning signal,' not a 'treatment target'
Chain 1 · Kidney:
Uric-acid stones: 10-15% of all kidney stones; unlike typical calcium-oxalate stones, they crystallise easily at urine pH < 5.5, appear low-density but visible on CT, and are nearly radiolucent on plain X-ray — which is why some patients with 'flank pain + haematuria but negative X-ray' are misdiagnosed for years. See the atlas `kidney-stones` sceneChronic urate nephropathy: long-term high SUA → urate crystal deposition in renal interstitium → chronic inflammation → tubulo-interstitial damage → gradual eGFR decline. Not inevitable, but patients with SUA > 10 mg/dL long-term show clearly accelerated CKD progressionAcute urate nephropathy (emergency): chemotherapy-induced tumour lysis syndrome (TLS) / severe dehydration + heavy alcohol / rare enzyme defects → SUA spikes → crystals block tubules → acute kidney injury. Emergency — see the red-flag sceneThe causality is partial: acute is clearly causal; chronic is partly causal in observational studies but Mendelian randomisation suggests SUA's causal effect on CKD is weaker than the observed association — meaning a large portion of 'high SUA + CKD' reflects shared metabolic background (hypertension + IR + MetSyn) acting on both organs
Chain 2 · Cardiovascular:
Observational links to hypertension, heart failure, CHD, and stroke — overall 'association + plausible mechanism + causality not fully established'Mechanism candidates: high SUA → endothelial dysfunction + oxidative stress + renin-angiotensin activation + microvascular inflammationKey clinical data: the CARES 2018 trial showed febuxostat had higher cardiovascular mortality vs allopurinol (not a test of treating hyperuricemia per se, but a reminder that 'urate-lowering drug effects on cardiovascular outcomes' are not neutral)Clinical implication: treating elevated SUA purely to reduce cardiovascular events is not recommended by any major guideline (ACR 2020 / EULAR 2016 / CSR 2024). In cardiovascular risk assessment, SUA is a 'warning signal,' not a 'treatment target'
MetSyn comorbidity + pregnancy + how to use
Chain 3 · Metabolic syndrome + MASLD comorbidity:High SUA / hyperglycaemia / dyslipidaemia / hypertension / central obesity / fatty liver form the metabolic-syndrome 'six pack', mutually reinforcing (see atlas `endocrine/metabolic-syndrome` + `nafld`)Bidirectional mechanism: high insulin → suppresses URAT1 excretion → ↑ SUA (insulin resistance drives hyperuricemia); and fructose → hepatic KHK → AMP → ↑ urate while fructose → ↑ visceral fat → ↑ IR, forming a positive feedback loopClinical practice: when a check-up flags high SUA, also assess waist + BP + fasting glucose + HbA1c + TG + HDL + liver enzymes. Looking at SUA alone is wasteful
Pregnancy-related (subset):
Preeclampsia + pregnancy-induced hypertension: high SUA is one of the early biomarkers; not a treatment target, but a 'monitor closely' signalAny pregnancy with the triad of high SUA + hypertension + proteinuria requires immediate obstetric evaluation
How to use this information:
When you see a high SUA on a lab report, don't only worry about future gout — treat it as a metabolic-health flag. It's often one of the earliest signs that insulin resistance is approaching, sometimes earlier than fasting glucoseThe real intervention is waist + sugary drinks + exercise + sleep — these change the upstream driver, not just the lab valueHigh SUA is not a 'diagnosis to panic about', but it's also not a 'meaningless red digit on the report'
Chapter 4
Diet leverage · counterintuitive
Diet leverage · counterintuitive
Real dietary priorities for hyperuricemia look nothing like the 1980s textbook. The actual levers are a small set, and 'no spinach, no tofu' isn't on it.
Lever 1 · Sugary drinks + juice + bubble tea:
The most disruptive finding in gout / hyperuricemia diet science of the past 20 yearsChoi 2008 BMJ (HPFS men): SSDs ≥ 1/day → gout risk ↑ 85%, ≥ 2/day ↑ 102%; still significant after adjusting for BMI + activity + purine intakeChoi 2010 JAMA (women): SSDs ≥ 1/day → risk ↑ 74%; 100% fruit juice also ↑ 41%Imamura 2015 BMJ meta: SSDs + juice consistently raise T2D risk — same driver shared with hyperuricemiaStanhope 2009 RCT: a single large fructose-sweetened beverage → SUA ↑ 0.5-1.5 mg/dL within 30-60 minutesMechanism in atlas `fructose-metabolism/khk` L4: fructose → hepatic KHK → adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. burned → AMP → urate. Unlike glucokinase, KHK has no energy-state feedback — fructose is always acceptedSingle-largest practical ROI: swap daily milk tea / cola / sweetened coffee for unsweetened tea / Americano / sparkling water
Lever 1 · Sugary drinks + juice + bubble tea:
The most disruptive finding in gout / hyperuricemia diet science of the past 20 yearsChoi 2008 BMJ (HPFS men): SSDs ≥ 1/day → gout risk ↑ 85%, ≥ 2/day ↑ 102%; still significant after adjusting for BMI + activity + purine intakeChoi 2010 JAMA (women): SSDs ≥ 1/day → risk ↑ 74%; 100% fruit juice also ↑ 41%Imamura 2015 BMJ meta: SSDs + juice consistently raise T2D risk — same driver shared with hyperuricemiaStanhope 2009 RCT: a single large fructose-sweetened beverage → SUA ↑ 0.5-1.5 mg/dL within 30-60 minutesMechanism in atlas `fructose-metabolism/khk` L4: fructose → hepatic KHK → adenosine triphosphate: The cell's universal energy currency — almost everything that costs energy spends it. burned → AMP → urate. Unlike glucokinase, KHK has no energy-state feedback — fructose is always acceptedSingle-largest practical ROI: swap daily milk tea / cola / sweetened coffee for unsweetened tea / Americano / sparkling water
Beer + seafood + counterintuitive plant purines
Lever 2 · Beer > spirits > red wine:Choi 2004 Lancet: beer is the strongest signal (high purines + alcohol), spirits intermediate (mainly suppress excretion), red wine weak at 1 glass/dayComplete abstinence approximately halves flare rateThe practical move for most patients is 'stop the beer first', not 'quit all alcohol immediately' — the latter rarely sticks
Lever 3 · Seafood + organ meats + some red meat:
Choi 2004 NEJM: highest vs lowest seafood quintile → gout risk ↑ 51%; red meat ↑ 41%High-purine: sardine + anchovy + herring + oyster + shrimp + crab + squid + organ meats (liver / kidney / brain)Moderate: chicken + beef + porkThis is not 'never again' — it's the association with chronic high intake. Seafood once or twice a week isn't a problem; daily hotpot organs + skewer feasts are
Counterintuitive: plant purines barely add risk:
Choi 2004 NEJM is the field's most disruptive paper: spinach / broccoli / asparagus / mushrooms / legumes — high-purine plant foods show no significant association with gout riskSoy + tofu actually reduce gout risk (protein substitution + isoflavones)This is why the atlas keeps repeating: the older 'no spinach, no tofu' advice is built on outdated purine-content tables, and modern epidemiology has overturned itPractical: do not restrict high-purine vegetables
Protective factors + mixed vitamin C evidence
Protective factors (mild but real):Cherries (Zhang 2012): equivalent of 10-12 cherries/day → flare risk ↓ 35%Coffee (Choi 2007): ≥ 4 cups/day → gout risk ↓ 40%; partially via XO inhibition + promoting excretion; prefer black / AmericanoLow-fat dairy / unsweetened yogurt (Choi 2004 NEJM + Dalbeth 2010 RCT): 240-500 mL/day associated with ~ 40% ↓ gout, and acutely lowers SUA. The most underrated single food interventionAdequate water: ≥ 2 L/day (≥ 3 L for gout / recurrent urate stones)
Vitamin C — mixed evidence:
Early Choi 2009 Arch Intern Med suggested 500 mg/day mildly lowers SUA + gout riskLater RCT (Stamp 2013) found limited SUA reduction in established gout (~ 0.1-0.3 mg/dL)High-dose vitamin C supplements (> 1000 mg/day) associate with increased kidney-stone risk (see atlas `kidney-stones`)Practical: don't rely on vitamin C as a primary urate-lowering tool, but dietary vitamin C from food is fine
Weight loss pace + overall pattern + linkbacks
Weight loss — important but not too fast:Long-term loss (5-10% over 3-6 months) → sustained SUA reduction + fewer flaresBut rapid loss (very-low-calorie / prolonged fasting / keto induction) → ketones compete for tubular excretion → transient SUA surge → can trigger a flareIn people with a flare history, discuss bridging prophylactic ULT with the physician during a weight-loss programme
Overall dietary pattern:
DASH + Mediterranean: vegetables + whole grains + fish + nuts + low-fat dairy + sodium control — simultaneously lowers SUA + BP + T2D riskWestern pattern (high animal protein + high sugar + ultra-processed): consistently associated with high SUADon't obsess over per-food purine gram counts — overall pattern matters far more than single-food calculations
Atlas linkbacks: `gout` (same island, fuller dietary triggers) · `fructose-metabolism/khk` L4 · `ultra-processed-foods` · `kidney-stones` · `endocrine/metabolic-syndrome`.
Chapter 5
Asymptomatic · treat or not
Asymptomatic · treat or not
'My check-up shows SUA 8.5 mg/dL but I've never had gout — should I take medication?' is the single most common question in hyperuricemia clinics and the most frequent point of over-prescription.
Mainstream answer: asymptomatic hyperuricaemia (ASU) is not recommended for drug treatment (FitzGerald 2020 ACR / EULAR 2016 / most regional guidelines agree):
Most people with high SUA never have a flare — treating everyone by threshold has a poor NNT and adds real drug side-effect exposureULT drugs (especially allopurinol) carry a genuine hypersensitivity risk in Asian populations (HLA-B*5801 → Stevens-Johnson / TEN, see below)'Better SUA number' ≠ 'better outcome': the CARES trial showed febuxostat lowered SUA but raised cardiovascular mortality vs allopurinol — a warning that 'good lab ≠ better patient'
ACR 2020 strongly recommends starting ULT when:
≥ 2 flares/yearAny visible tophiGout-related imaging damage (X-ray / ultrasound shows erosion / crystal deposition)CKD ≥ 3 + prior gout flareRecurrent uric-acid stones (even without gout)
ACR 2020 conditionally recommends (individualised discussion):
First flare with SUA > 9 mg/dLFirst flare with CKD ≥ 3 / uric-acid stones / stone historyThese are 'don't necessarily start immediately, but worth a serious conversation with the physician'
Mainstream answer: asymptomatic hyperuricaemia (ASU) is not recommended for drug treatment (FitzGerald 2020 ACR / EULAR 2016 / most regional guidelines agree):
Most people with high SUA never have a flare — treating everyone by threshold has a poor NNT and adds real drug side-effect exposureULT drugs (especially allopurinol) carry a genuine hypersensitivity risk in Asian populations (HLA-B*5801 → Stevens-Johnson / TEN, see below)'Better SUA number' ≠ 'better outcome': the CARES trial showed febuxostat lowered SUA but raised cardiovascular mortality vs allopurinol — a warning that 'good lab ≠ better patient'
ACR 2020 strongly recommends starting ULT when:
≥ 2 flares/yearAny visible tophiGout-related imaging damage (X-ray / ultrasound shows erosion / crystal deposition)CKD ≥ 3 + prior gout flareRecurrent uric-acid stones (even without gout)
ACR 2020 conditionally recommends (individualised discussion):
First flare with SUA > 9 mg/dLFirst flare with CKD ≥ 3 / uric-acid stones / stone historyThese are 'don't necessarily start immediately, but worth a serious conversation with the physician'
ULT drug classes + early-treat
A few situations genuinely warrant early treatment:Tumour lysis syndrome (TLS) risk in chemotherapy / haematologic malignancy: emergency / prophylactic allopurinol + aggressive hydration + rasburicase if neededChronic kidney disease + recurrent uric-acid stones: even without gout, urine alkalinisation + low-dose allopurinol may be consideredRare enzyme defects (Lesch-Nyhan / HPRT deficiency): lifelong
Three drug classes:
Allopurinol — first-line: XO inhibitor. Start at 100 mg/day, titrate every 2-5 weeks to SUA target (< 6 mg/dL, < 5 in tophi patients). Cheap + extensive long-term data. **In East Asians, HLA-B*5801 genotyping is strongly recommended before prescribing**: carriers have > 100× relative risk of fatal Stevens-Johnson / TEN (FitzGerald 2020 ACR + Taiwan NHI experience); NNT_screen ≈ 1/250 to prevent one severe cutaneous reaction. If positive → switch to febuxostat or uricosuricFebuxostat — second-line: selective XO inhibitor. 40-80 mg/day, not heavily renal-dependent. CARES 2018 showed higher cardiovascular mortality vs allopurinol — FDA black-box warning; high-CV-risk patients should prefer allopurinolUricosurics (probenecid / benzbromarone / lesinurad): second-line, ↑ excretion by inhibiting URAT1. Not suitable for CKD or uric-acid stone patients (raises crystal risk)
Initiation trap + duration
ULT initiation trap — must know:When ULT drops SUA rapidly, existing intra-articular crystals partly dissolve → triggering acute flares (expected, not treatment failure)Standard practice: bridge ULT initiation with colchicine 0.5 mg × 1-2/day (or low-dose NSAID) for 3-6 monthsDo not self-discontinue ULT during the initiation flare — the most common 'treatment makes me worse' mistake
ULT duration:
Most patients lifelongA few (large weight loss + tophi resolved + 1-2 years flare-free + stable SUA at goal) can discuss tapering with the physicianDo not self-stop — recurrence rate is high
Red flags + two-line summary
Red flags · go to ER:AKI after chemotherapy + SUA spike / massive rhabdomyolysis: suggests TLS or acute urate nephropathy — emergency (aggressive fluids + allopurinol / rasburicase + urine alkalinisation + dialysis if needed)Gout flare with fever + severe joint swelling + chills: cannot rule out septic arthritis — emergency joint aspiration requiredPregnancy + high SUA + hypertension + proteinuria: preeclampsia evaluation, obstetric emergencyRash + fever + mucosal erosion + systemic symptoms 1-8 weeks after starting allopurinol / febuxostat / sulfonamides: Stevens-Johnson / TEN / DRESS — stop drug immediately and go to the ER (life-threatening, not for home observation)
Two-line summary:
Check-up shows high SUA, no flare, no stones → don't medicate; use it as a metabolic-health flag and address waist + BP + glucose + lipids + lifestyleRecurrent flares / tophi / uric-acid stones / CKD comorbidity → ULT is the evidence-based decision; discuss the right drug + HLA-B*5801 testing + bridging prophylaxis with the physician, not at the 'supplement-aisle' level
Atlas linkbacks: `gout` (acute flare + ULT detail) · `kidney-stones` (uric-acid stone management) · `fructose-metabolism/khk` L4 · `endocrine/metabolic-syndrome`.